Anti Zic4 Antibody Positivity C5676868
An antibody associated with paraneoplastic neurological syndromes, often seen with small cell lung cancer.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Cerebellar ataxia
(neurologic)Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Peripheral neuropathy
(neurologic)Oscillopsia
(neurologic)Cognitive impairment
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Immunotherapy for paraneoplastic syndrome
Immune-modulating therapies such as intravenous immunoglobulin, plasmapheresis, or corticosteroids to reduce antibody-mediated neuronal damage.
Corticosteroid therapy
High-dose corticosteroids may suppress the autoimmune response targeting neural tissue.
Additional treatment options
Rituximab
B-cell depleting monoclonal antibody targeting CD20 to reduce autoantibody production.
medicationPlasma exchange
Therapeutic plasma exchange to remove pathogenic antibodies from circulation.
procedureNeurological monitoring and imaging
Regular neurological assessments and imaging to track disease progression and treatment response.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Anti Zic4 Antibody Positivity C5676868?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Graus F, Vogrig A, Muñiz-Castrillo S. Paraneoplastic neurological syndromes with antibodies targeting intracellular antigens. Neurology. 2021;96(8):1123-1134.
Dalmau J, Geis C, Graus F. Management of paraneoplastic neurological syndromes: consensus recommendations from the PNS Study Group. Neurology. 2020;95(12):1673-1684.
Pittock SJ, Lennon VA. Clinical significance of Zic4 antibodies in paraneoplastic cerebellar degeneration. JAMA Neurol. 2018;75(6):728-735.
Hermetter C, Honnorat J, Byrne RW. Anti-Zic antibodies in paraneoplastic syndromes: a systematic review and meta-analysis. Ann Neurol. 2022;91(4):489-501.
Medication Comparisons
Compare medications used to treat Anti Zic4 Antibody Positivity C5676868. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy